Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: awareness warranted for 2017/18 season.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Rondy, MarcGherasim, Alin
Casado, Itziar
Launay, Odile
Rizzo, Caterina
Pitigoi, Daniela
Mickiene, Aukse
Marbus, Sierk D
Machado, Ausenda
Syrjänen, Ritva K
Pem-Novose, Iva
Horváth, Judith Krisztina
Larrauri, Amparo
Castilla, Jesús
Vanhems, Philippe
Alfonsi, Valeria
Ivanciuc, Alina E
Kuliese, Monika
van Gageldonk-Lafeber, Rianne
Gomez, Veronica
Ikonen, Niina
Lovric, Zvjezdana
Ferenczi, Annamária
Moren, Alain
Type
ArticleLanguage
en
Metadata
Show full item recordTitle
Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: awareness warranted for 2017/18 season.Published in
Euro Surveill 2017; 22(41):17000645Publiekssamenvatting
In a multicentre European hospital study we measured influenza vaccine effectiveness (IVE) against A(H3N2) in 2016/17. Adjusted IVE was 17% (95% confidence interval (CI): 1 to 31) overall; 25% (95% CI: 2 to 43) among 65-79-year-olds and 13% (95% CI: -15 to 30) among those ≥ 80 years. As the A(H3N2) vaccine component has not changed for 2017/18, physicians and public health experts should be aware that IVE could be low where A(H3N2) viruses predominate.PMID
29043961ae974a485f413a2113503eed53cd6c53
10.2807/1560-7917.ES.2017.22.41.17-00645
Scopus Count
Collections
Related articles
- 2011-12 seasonal influenza vaccines effectiveness against confirmed A(H3N2) influenza hospitalisation: pooled analysis from a European network of hospitals. A pilot study.
- Authors: Rondy M, Puig-Barbera J, Launay O, Duval X, Castilla J, Guevara M, Costanzo S, de Gaetano Donati K, Moren A
- Issue date: 2013
- 2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B: estimates from a European network of hospitals.
- Authors: Rondy M, Launay O, Puig-Barberà J, Gefenaite G, Castilla J, de Gaetano Donati K, Galtier F, Hak E, Guevara M, Costanzo S, European hospital IVE network, Moren A
- Issue date: 2015 Jan 15
- Vaccine effectiveness against influenza A(H3N2) and B among laboratory-confirmed, hospitalised older adults, Europe, 2017-18: A season of B lineage mismatched to the trivalent vaccine.
- Authors: Rose AMC, Kissling E, Gherasim A, Casado I, Bella A, Launay O, Lazăr M, Marbus S, Kuliese M, Syrjänen R, Machado A, Kurečić Filipović S, Larrauri A, Castilla J, Alfonsi V, Galtier F, Ivanciuc A, Meijer A, Mickiene A, Ikonen N, Gómez V, Lovrić Makarić Z, Moren A, Valenciano M, I-MOVE Hospital study team
- Issue date: 2020 May
- Moderate influenza vaccine effectiveness against hospitalisation with A(H3N2) and A(H1N1) influenza in 2013-14: Results from the InNHOVE network.
- Authors: Rondy M, Castilla J, Launay O, Costanzo S, Ezpeleta C, Galtier F, de Gaetano Donati K, Moren A
- Issue date: 2016 May 3
- Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe.
- Authors: Kissling E, Rondy M, I-MOVE/I-MOVE+ study team
- Issue date: 2017 Feb 16